Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What are the potential risks of cosentyx in children?Vascepa prescribing information take with food?Did your doctor discuss specific foods to avoid on lipitor?How does kadcyla's success rate compare to biosimilars in real world use?Does lipitor's dosage affect how strong pain meds work?
See the DrugPatentWatch profile for vascepa
What discounts are available for Vascepa right now? Several coupons and patient assistance programs currently offer savings on Vascepa. A common program provides a savings card that brings the copay down to as low as $9 for a 30-day supply when used at retail pharmacies. This applies only to commercially insured patients and has an annual maximum savings of $150 per prescription fill. How does the Vascepa savings card work? The savings card covers the difference between the list price and your copay, helping patients with commercial insurance cover the remaining cost after their insurance pays. Commercially insured patients can enroll online or at their pharmacy to use it. Uninsured patients or those whose insurance does not cover Vascepa may still benefit from other assistance options. How does Vascepa compare to generic icosapent ethyl? Generic versions of icosapent ethyl have entered the market and usually cost far less than brand-name Vascepa. Generics often sell around $300–$400 per month, far below the list price of brand-name Vascepa, which exceeds $300 per month at many pharmacies. Many insurance plans now favor generics over the brand. When does Vascepa's patent expire? Vascepa's primary compound patent expired in 2020. Remaining patents covering formulations and methods of use are scheduled to expire in 2030 and 2033. Companies have challenged these remaining patents, but the current rights holder still maintains exclusive rights under those claims. Who makes Vascepa? Amarin Pharma owns the rights to Vascepa. Amarin has faced litigation over its remaining patents and lost a case in 2020 that allowed generic versions to launch.
Other Questions About Vascepa :